浏览全部资源
扫码关注微信
Establishment and Validation of Clinical Prediction Model for 1-year MACEs Risk After PCI in CHD Patients with Blood Stasis Syndrome
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 20, Pages: 69-80(2023)
- 作者机构：
1.北京中医药大学，北京 100029
2.中日友好医院，北京 100029
3.中国中医科学院 广安门医院，北京 100053
- 作者简介：
- 基金信息：
DOI：10.13422/j.cnki.syfjx.20231594
CLC： R242;R2-031;R287;R259;R541.4Published：20 October 2023，
Published Online：13 February 2023，
Received：12 November 2022，
- 稿件说明：
扫 描 看 全 文
陶诗怡,于林童,杨德爽等.冠心病血瘀证PCI术后1年MACEs风险临床预测模型的建立与验证[J].中国实验方剂学杂志,2023,29(20):69-80.
TAO Shiyi,YU Lintong,YANG Deshuang,et al.Establishment and Validation of Clinical Prediction Model for 1-year MACEs Risk After PCI in CHD Patients with Blood Stasis Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(20):69-80.
陶诗怡,于林童,杨德爽等.冠心病血瘀证PCI术后1年MACEs风险临床预测模型的建立与验证[J].中国实验方剂学杂志,2023,29(20):69-80. DOI： 10.13422/j.cnki.syfjx.20231594.
TAO Shiyi,YU Lintong,YANG Deshuang,et al.Establishment and Validation of Clinical Prediction Model for 1-year MACEs Risk After PCI in CHD Patients with Blood Stasis Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(20):69-80. DOI： 10.13422/j.cnki.syfjx.20231594.
摘要
目的
2
构建并验证冠心病血瘀证PCI术后1年主要不良心血管事件（MACEs）风险临床预测模型。
方法
2
回顾性收集中日友好医院中西医结合心内科2019年9月1日至2021年3月31日确诊冠心病血瘀证并首次接受经皮冠状动脉介入治疗（PCI）的连续病例，统一采集基本临床特征和相关检验检查指标，按7∶3比例分为训练集和验证集，并根据1年内是否发生MACEs进一步把各组分为MACE组和非MACE组。采用最小绝对收缩选择算子（Lasso）回归分析筛选冠心病血瘀证PCI术后1年MACEs预测因素，构建多因素Logistic回归临床预测模型并筛选独立影响因素。通过Hosmer-Lemeshow检验评价模型拟合优度，采用受试者工作特征（ROC）曲线下面积（AUC）、校准曲线、策曲线分析（DCA）和临床影响曲线（CIC）评估模型的区分度、校准度及临床影响力。
结果
2
共筛选连续病例731例，最终纳入404例，训练集283例，验证集121例。Lasso回归分析筛选出年龄、性别、空腹血糖（FPG）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、同型半胱氨酸（Hcy）、肱踝动脉脉搏波速度（baPWV）、血管舒张功能（FMD）、左室射血分数（LVEF）、Gensini积分共10个变量为影响结局的因素。通过多因素Logistic回归分析，初步判断男性、高FMD、高LVEF是保护因素，年龄、高FPG、高TG、高LDL-C、高Hcy、高baPWV、高Gensini积分是危险因素。其中，年龄、FPG、TG、Hcy、LDL-C、LVEF和Gensini积分为独立影响因素。构建出冠心病血瘀证PCI术后1年MACEs临床预测模型，Hosmer-Lemeshow检验得到
χ
2
=12.371，
P
=0.14；AUC为0.90；阈值概率
>
10%时，使用该预测模型预测冠心病血瘀证PCI术后1年MACEs风险比对所有患者实施干预方案更有利，阈值
>
60%时，阳性估计值越接近真实患病数。
结论
2
此模型有助于早期识别冠心病血瘀证PCI术后1年MACEs风险，便于进行早期临床决策和干预，对改善患者预后有重要指导意义。同时期待更多中心、更大样本的研究对该模型进行进一步验证、完善和更新。
Abstract
Objective
2
To establish and validate a clinical prediction model for 1-year major adverse cardiovascular events（MACEs）risk after percutaneous coronary intervention （PCI） in coronary heart disease （CHD） patients with blood stasis syndrome.
Method
2
The consecutive CHD patients diagnosed with blood stasis syndrome in the Department of Integrative Cardiology at China-Japan Friendship Hospital from September 1， 2019 to March 31， 2021 were selected for a retrospective study， and basic clinical features and relevant indicators were collected. Eligible patients were classified into a derivation set and a validation set at a ratio of 7∶3， and each set was further divided into a MACEs group and a non-MACEs group. The factors affecting the outcomes were screened out by least absolute shrinkage and selection operator （Lasso） and used to establish a logistic regression model and identify independent prediction variables. The goodness-of-fit of the model was evaluated by the Hosmer-Lemeshow test， and the area under curve （AUC） of the receiver operating characteristic （ROC） curve， calibration curve， decision curve analysis （DCA）， and clinical impact curve （CIC） were employed to evaluate the discrimination， calibration， and clinical impact of the model.
Result
2
A total of 731 consecutive patients were assessed and 404 eligible patients were enrolled， including 283 patients in the derivation set and 121 patients in the validation set. Lasso identified ten variables influencing outcomes， which included age， sex， fasting plasma glucose （FPG）， triglyceride （TG）， low-density lipoprotein cholesterol （LDL-C）， homocysteine （Hcy）， brachial-ankle pulse wave velocity （baPWV）， flow-mediated dilatation （FMD）， left ventricular ejection fraction （LVEF）， and Gensini score. The multivariate Logistic regression preliminarily identified age， FPG， TG， Hcy， LDL-C， LVEF， and Gensini score as the independent variables that influenced the outcomes. Of these variables， male， high FMD and high LVEF were protective factors， and the rest were risk factors. The prediction model for 1-year MACEs risk after PCI in CHD patients with blood stasis syndrome showed
χ
2
=12.371 （
P
=0.14） in Hosmer-Lemeshow test and the AUC of 0.90. With the threshold probability
>
10%， the model showed better prediction performance for 1-year MACEs risk after PCI in CHD patients with blood stasis syndrome than for that in all the patients. With the threshold probability
>
60%， the estimated value was much closer to the real number of patients.
Conclusion
2
The established clinical prediction model facilitates the early prediction of 1-year MACEs risk after PCI in CHD patients with blood stasis syndrome， which can provide ideas for the precise treatment of CHD patients after PCI and has guiding significance for improving the prognosis of the patients. Meanwhile， multi-center studies with larger sample sizes are expected to further validate， improve， and update the model.
关键词
冠状动脉粥样硬化性心脏病经皮冠状动脉介入治疗临床预测模型列线图预后相关性
Keywords
coronary heart diseasepercutaneous coronary interventionclinical prediction modelnomogramprognosiscorrelation
references
ROTH G A，MENSAH G A，JOHNSON C O，et al.Global burden of cardiovascular diseases and risk factors，1990-2019：Update from the GBD 2019 study［J］.J Am Coll Cardiol，2020，76（25）：2982-3021.
国家心血管病中心.中国心血管健康与疾病报告2020［J］.心肺血管病杂志，2021，40（9）：885-889.
LAWTON J S，TAMIS-HOLLAND J E，BANGALORE S，et al.2021 ACC/AHA/SCAI guideline for coronary artery revascularization：A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines［J］.Circulation，2022，145（3）：e18-e114.
霍勇.霍勇教授数说中国PCI的发展［EB/OL］.（2021-4-24）［2022-11-12］.https：//ccif2021.sciconf.cn/cn/web/index/10924_785008_29775https://ccif2021.sciconf.cn/cn/web/index/10924_785008_29775.
世界中医药联合会心血管病专业委员会，中国中西医结合学会心血管病专业委员会，中华中医药学会介入心脏病学会，等.冠状动脉血运重建术后心绞痛中西医结合诊疗指南［J］.中国中西医结合杂志，2020，40（11）：1298-1307.
ALEXANDER K P，COWPER P A，KEMPF J A，et al.Profile of chronic and recurrent angina pectoris in a referral population［J］.Am J Cardiol，2008，102（10）：1301-1306.
DANGAS G D，CLAESSEN B E，CAIXETA A，et al.In-stent restenosis in the drug-eluting stent era［J］.J Am Coll Cardiol，2010，56（23）：1897-1907.
VARENNE O，COOK S，SIDERIS G，et al.Drug-eluting stents in elderly patients with coronary artery disease（SENIOR）：A randomised single-blind trial［J］.Lancet，2018，391（10115）：41-50.
FANAROFF A C，ZAKROYSKY P，WOJDYLA D，et al.Relationship between operator volume and long-term outcomes after percutaneous coronary intervention［J］.Circulation，2019，139（4）：458-472.
MADHAVAN M V，KIRTANE A J，REDFORS B，et al.Stent-related adverse events >1 year after percutaneous coronary intervention［J］.J Am Coll Cardiol，2020，75（6）：590-604.
毛静远，牛子长，张伯礼.近40年冠心病中医证候特征研究文献分析［J］.中医杂志，2011，52（11）：958-961.
李彬，毕颖斐，赵志强，等.PCI与CABG术后中医证候特征的专家调查［J］.天津中医药，2013，30（8）：503-505.
王彦.血瘀与冠心病的相关性研究概况［J］.中医杂志，2012，53（7）：613-616.
刘冠男.经皮冠状动脉介入术后主要不良心脏事件与中医证候相关性研究［D］.北京：中国中医科学院，2020.
李长江.冠心病患者支架植入术后中医证候要素变化及不同证候要素中Betatrophin和血红素氧合酶1表达变化的研究［D］.泸州：西南医科大学，2018.
中国心血管病风险评估和管理指南编写联合委员会.中国心血管病风险评估和管理指南［J］.中国循环杂志，2019，34（1）：4-28.
RANSTAM J，COOK J A，COLLINS G S.Clinical prediction models［J］.Br J Surg，2016，103（13）：1886.
MOONS K G，ALTMAN D G，REITSMA J B，et al.Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis（TRIPOD）：Explanation and elaboration［J］.Ann Intern Med，2015，162（1）：W1-W73.
ADAMS S T，LEVESON S H.Clinical prediction rules［J］.BMJ，2012，doi：10.1136/bmj.d8312http://dx.doi.org/10.1136/bmj.d8312.
MOONS K G，ROYSTON P，VERGOUWE Y，et al.Prognosis and prognostic research：What，why，and how？［J］.BMJ，2009，338：b375.
谷鸿秋，周支瑞，章仲恒，等.临床预测模型：基本概念、应用场景及研究思路［J］.中国循证心血管医学杂志，2018，10（12）：1454-1456，1462.
KNUUTI J，WIJNS W，SARASTE A，et al.2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes［J］.Eur Heart J，2020，41（3）：407-477.
中国中西医结合学会活血化瘀专业委员会，陈可冀，史大卓，等.冠心病血瘀证诊断标准［J］.中国中西医结合杂志，2016，36（10）：1162.
DEVEREUX R B，ALONSO D R，LUTAS E M，et al.Echocardiographic assessment of left ventricular hypertrophy：Comparison to necropsy findings［J］.Am J Cardiol，1986，57（6）：450-458.
RAMPIDIS G P，BENETOS G，BENZ D C，et al.A guide for Gensini score calculation［J］.Atherosclerosis，2019，287：181-183.
KANNEL W B，MCGEE D，GORDON T.A general cardiovascular risk profile：The framingham study［J］.Am J Cardiol，1976，38（1）：46-51.
WILSON P W，D'AGOSTINO R B，LEVY D，et al.Prediction of coronary heart disease using risk factor categories［J］.Circulation，1998，97（18）：1837-1847.
LIU J，HONG Y，SR D R B，et al.Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study［J］.JAMA，2004，291（21）：2591-2599.
SR D R B，VASAN R S，PENCINA M J，et al.General cardiovascular risk profile for use in primary care：The Framingham heart study［J］.Circulation，2008，117（6）：743-753.
HIPPISLEY-COX J，COUPLAND C，VINOGRADOVA Y，et al.Derivation and validation of QRISK，a new cardiovascular disease risk score for the United Kingdom：Prospective open cohort study［J］.BMJ，2007，335（7611）：136.
GOFF D C，LLOYD-JONES D M，BENNETT G，et al.2013 ACC/AHA guideline on the assessment of cardiovascular risk：A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines［J］.Circulation，2014，129（25 Suppl 2）：S49-S73.
WILSON P W，SR D R，BHATT D L，et al.An international model to predict recurrent cardiovascular disease［J］.Am J Med，2012，125（7）：695-703.
DORRESTEIJN J A，VISSEREN F L，WASSINK A M，et al.Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease：The SMART risk score［J］.Heart，2013，99（12）：866-872.
吴锡桂，赖声汉，高红，等.首都钢铁公司988名男性工人冠心病危险因素的多元分析［J］.中华心血管病杂志，1983，11（1）：28-32.
YANG X，LI J，HU D，et al.Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population：The China-PAR project（prediction for ASCVD risk in China）［J］.Circulation，2016，134（19）：1430-1440.
TANG X，ZHANG D，HE L，et al.Performance of atherosclerotic cardiovascular risk prediction models in a rural Northern Chinese population：Results from the Fangshan cohort study［J］.Am Heart J，2019，211：34-44.
YANG X L，CHEN J C，LI J X，et al.Risk stratification of atherosclerotic cardiovascular disease in Chinese adults［J］.Chronic Dis Transl Med，2016，2（2）：102-109.
LU X，LIU Z，CUI Q，et al.A polygenic risk score improves risk stratification of coronary artery disease：A large-scale prospective Chinese cohort study［J］.Eur Heart J，2022，43（18）：1702-1711.
孙屿昕，侯文斌，陈韵如，等.中医药个体预后与诊断预测模型研究报告规范——TRIPOD-TCM清单［J］.中医杂志，2022，63（10）：936-942.
NOWBAR A N，HOWARD J P，FINEGOLD J A，et al.2014 global geographic analysis of mortality from ischaemic heart disease by country，age and income：Statistics from World Health Organisation and United Nations［J］.Int J Cardiol，2014，174（2）：293-298.
KATTAINEN A，SALOMAA V，HÄRKÄNEN T，et al.Coronary heart disease：From a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s［J］.Eur Heart J，2006，27（3）：296-301.
申倩南，王东侠，翟恒博，等.性别和年龄对急性ST段抬高型心肌梗死患者住院期间主要不良心脑血管事件的影响［J］.中华心血管病杂志，2017，45（4）：288-293.
侯春霞，杨菲菲，熊敏俊，等.超高龄冠心病患者冠状动脉介入术后的随访研究［J］.心脏杂志，2022，34（5）：537-540，551.
盛英杰，韩英，裴丽峰，等.年龄≥75岁冠心病患者实施经皮冠状动脉介入治疗的风险及效果评价［J］.中国现代药物应用，2022，16（1）：38-40.
SANGIORGI G，RUMBERGER J A，SEVERSON A，et al.Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans：A histologic study of 723 coronary artery segments using nondecalcifying methodology［J］.J Am Coll Cardiol，1998，31（1）：126-133.
NEWMAN A B，NAYDECK B L，SUTTON-TYRRELL K，et al.Coronary artery calcification in older adults to age 99：Prevalence and risk factors［J］.Circulation，2001，104（22）：2679-2684.
COSTA J D R，SOUSA A G M R，MOREIRA A C，et al.Drug-eluting stent implantation for the treatment of drug-eluting stent restenosis：Longterm analysis of the DESIRE registry［J］.Rev Bras Cardiol Invasiva，2007，16（3）：273-278.
SAVONITTO S，CAVALLINI C，PETRONIO A S，et al.Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome：A randomized controlled trial［J］.JACC Cardiovasc Interv，2012，5（9）：906-916.
赵雪东，赵冠棋，王晓，等.女性ST段抬高型心肌梗死合并多支血管病变行直接经皮冠脉介入术预后分析［J］.中华急诊医学杂志，2022，31（7）：895-900.
MEHILLI J，KASTRATI A，DIRSCHINGER J，et al.Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting［J］.JAMA，2000，284（14）：1799-1805.
PETERSON E D，LANSKY A J，KRAMER J，et al.Effect of gender on the outcomes of contemporary percutaneous coronary intervention［J］.Am J Cardiol，2001，88（4）：359-364.
MEHTA P K，JOHNSON B D，KENKRE T S，et al.Sudden cardiac death in women with suspected ischemic heart disease，preserved ejection fraction，and no obstructive coronary artery disease：A report from the women's ischemia syndrome evaluation study［J］.J Am Heart Assoc，2017，6（8）
KHARE M M，CURSIO J F，LOCKLIN C A，et al.Lifestyle intervention and cardiovascular disease risk reduction in low-income Hispanic immigrant women participating in the Illinois WISEWOMAN program［J］.J Community Health，2014，39（4）：737-746.
KOK M M，VON BIRGELEN C，SATTAR N，et al.Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population［J］.EuroIntervention，2018，14（9）：e1049-e1056.
LIMA-FILHO M O，FIGUEIREDO G L，FOSS-FREITAS M C，et al.Predictors of restenosis after percutaneous coronary intervention using bare-metal stents：A comparison between patients with and without dysglycemia［J］.Braz J Med Biol Res，2010，43（6）：572-579.
YI M，CAO Q，TANG W H，et al.Day-to-day fasting plasma glucose variability on the short-term prognosis of ST-segment elevation myocardial infarction：A retrospective cohort study［J］.Clin Cardiol，2022，45（12）：1246-1254.
WANG K，CHEN L，LIU L，et al.The effects of atorvastatin on interventional therapy in patients with acute myocardial infarction［J］.Minerva Med，2019，110（2）：101-106.
HU C，ZHANG J，LIU J，et al.Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular events：A cohort study from China［J］.Cardiovasc Diabetol，2020，19（1）：116.
LUO E，WANG D，YAN G，et al.High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention［J］.Cardiovasc Diabetol，2019，18（1）：150.
KLERK M，VERHOEF P，CLARKE R，et al.MTHFR 677C→T polymorphism and risk of coronary heart disease：A Meta-analysis［J］.JAMA，2002，288（16）：2023-2031.
Homocysteine Studies Collaboration.Homocysteine and risk of ischemic heart disease and stroke：A Meta-analysis［J］.JAMA，2002，288（16）：2015-2022.
KAPLAN P，TATARKOVA Z，SIVONOVA M K，et al.Homocysteine and mitochondria in cardiovascular and cerebrovascular systems［J］.Int J Mol Sci，2020，21（20）：7698.
齐晓勇，孟存良，谷剑，等.同型半胱氨酸与不稳定型心绞痛患者介入治疗早期并发症的关系［J］.临床心血管病杂志，2006，22（2）：73-76.
DE BREE A，VERSCHUREN W M，KROMHOUT D，et al.Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease［J］.Pharmacol Rev，2002，54（4）：599-618.
ROSS R.Atherosclerosis-An inflammatory disease［J］.N Engl J Med，1999，340（2）：115-126.
KIM J，BHUPATHIRAJU S N，HARRINGTON L B，et al.Oral postmenopausal hormone therapy and genetic risk on venous thromboembolism：Gene-hormone interaction results from a large prospective cohort study［J］.Menopause，2022，29（3）：293-303.
DIONISIO N，JARDÍN I，SALIDO G M，et al.Homocysteine，intracellular signaling and thrombotic disorders［J］.Curr Med Chem，2010，17（27）：3109-3119.
KOJOGLANIAN S A，JORGENSEN M B，WOLDE-TSADIK G，et al.Restenosis in intervened coronaries with hyperhomocysteinemia（RICH）［J］.Am Heart J，2003，146（6）：1077-1081.
SCHNYDER G，ROFFI M，FLAMMER Y，et al.Effect of homocysteine-lowering therapy with folic acid，vitamin B12，and vitamin B6 on clinical outcome after percutaneous coronary intervention：The Swiss Heart study：A randomized controlled trial［J］.JAMA，2002，288（8）：973-979.
WANG H，WU X，GU Y，et al.Relationship of noninvasive assessment of arterial stiffness with 10-year atherosclerotic cardiovascular disease（ASCVD） risk in a general middle-age and elderly population［J］.Int J Gen Med，2021，14：6379-6387.
KUVIN J T，PATEL A R，SLINEY K A，et al.Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease［J］.J Am Coll Cardiol，2001，38（7）：1843-1849.
HEIDENREICH P A，BOZKURT B，AGUILAR D，et al.2022 AHA/ACC/HFSA guideline for the management of heart failure：A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines［J］.Circulation，2022，145（18）：e895-e1032.
陶诗怡，于林童，王子涵，等.Logistic回归联合ROC曲线模型评价动脉弹性和内皮功能指标对绝经后冠心病血瘀证的诊断效能［J］.中国中药杂志，2022，47（8）：2244-2250.
THIJSSEN D，BRUNO R M，VAN MIL A，et al.Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans［J］.Eur Heart J，2019，40（30）：2534-2547.
PATTI G，PASCERI V，MELFI R，et al.Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation［J］.Circulation，2005，111（1）：70-75.
XIONG Z，ZHU C，ZHENG Z，et al.Relationship between arterial stiffness assessed by brachial-ankle pulse wave velocity and coronary artery disease severity assessed by the SYNTAX score［J］.J Atheroscler Thromb，2012，19（11）：970-976.
TAKASHIMA N，TURIN T C，MATSUI K，et al.The relationship of brachial-ankle pulse wave velocity to future cardiovascular disease events in the general Japanese population：The Takashima study［J］.J Hum Hypertens，2014，28（5）：323-327.
VLACHOPOULOS C，AZNAOURIDIS K，STEFANADIS C.Prediction of cardiovascular events and all-cause mortality with arterial stiffness：A systematic review and Meta-analysis［J］.J Am Coll Cardiol，2010，55（13）：1318-1327.
HANADA K，SASAKI S，SENO M，et al.Reduced left ventricular ejection fraction is a risk for sudden cardiac death in the early period after hospital discharge in patients with acute myocardial infarction［J］.Circ J，2022，86（10）：1490-1498.
GALLONE G，KANG J，BRUNO F，et al.Impact of left ventricular ejection fraction on procedural and long-term outcomes of bifurcation percutaneous coronary intervention［J］.Am J Cardiol，2022，172：18-25.
LIU Z，LIU L，ZHANG H，et al.Preventive effect observation of dapagliflozin on middle and later ventricular remodeling in patients with acute st segment elevation anterior wall myocardial infarction：A single-center，retrospective cohort study［J］.J Healthc Eng，2022，2022：3955914.
CHEN C，WU X，LI Y，et al.Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention（PCI）［J］.Ann Palliat Med，2021，10（5）：5455-5461.
SU Y M，ZHANG R，XU R F，et al.Triglyceride to high-density lipoprotein cholesterol ratio as a risk factor of repeat revascularization among patients with acute coronary syndrome after first-time percutaneous coronary intervention［J］.J Thorac Dis，2019，11（12）：5087-5095.
WANG K Y，ZHENG Y Y，WU T T，et al.Predictive value of gensini score in the long-term outcomes of patients with coronary artery disease who underwent PCI［J］.Front Cardiovasc Med，2021，8：778615.
ROSAMOND W，FLEGAL K，FURIE K，et al.Heart disease and stroke statistics——2008 update：A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee［J］.Circulation，2008，117（4）：e25-e146.
0
Views
21
下载量
0
CSCD
- H-PDFDownload
- L-PDFDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Postal code：100700
- Tel：010-84076882 Email：syfjx_2010@188.com
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
